Oncotarget

Reviews:

Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

Cristiana Pistol Tanase _, Elena Codrici, Ionela Daniela Popescu, Simona Mihai, Ana-Maria Enciu, Laura Georgiana Necula, Adrian Preda, Gener Ismail and Radu Albulescu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:18497-18512. https://doi.org/10.18632/oncotarget.14501

Metrics: PDF 2421 views  |   HTML 2406 views  |   ?  


Abstract

Cristiana Pistol Tanase1,2, Elena Codrici1, Ionela Daniela Popescu1, Simona Mihai1, Ana-Maria Enciu1,3, Laura Georgiana Necula1,4, Adrian Preda5, Gener Ismail6,8 and Radu Albulescu1,7

1 Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania

2 Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania

3 Department of Cell Biology and Histology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

4 Stefan S Nicolau Institute of Virology, Bucharest, Romania

5 Center for Uronephrology and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania

6 Center of Internal Medicine-Nephrology, Fundeni Clinical Institute, Bucharest, Romania

7 National Institute for Chemical Pharmaceutical R&D, Bucharest, Romania

8 Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Bucharest, Romania

Correspondence to:

Cristiana Tanase, email:

Keywords: prostate cancer, biomarkers, proteomics, mass spectrometry, prostasomes

Received: July 29, 2016 Accepted: December 27, 2016 Published: January 04, 2017

Abstract

The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment. Proteomic technologies such as MALDI-MS, SELDI-MS, i-TRAQ allow a qualitative/quantitative analysis of the proteome variations, in both serum and tumor tissue. A new trend in prostate cancer research is proteomic analysis of prostasomes (prostate-specific exosomes), for the discovery of new biomarkers. This paper provides an update of novel clinical tests used in research and clinical diagnostic, as well as of potential tissue or fluid biomarkers provided by extensive proteomic research data.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14501